PedAM
Pediatric Disease Annotations & Medicines
| Disease | irritable bowel syndrome |
| Phenotype | C0009806|constipation |
| Sentences | 59 |
| PubMedID- 22444104 | Apart from lubiprostone, treatment of irritable bowel syndrome with constipation is limited to small studies (with poor descriptions of side effects), although lubiprostone and selective serotonin reuptake inhibitors appear safe. |
| PubMedID- 26579459 | The u. s. fda has approved 290 μg of linaclotide daily for irritable bowel syndrome with constipation and 145 μg daily for chronic idiopathic constipation38. |
| PubMedID- 21848795 | Epidemiology of functional constipation and comparison with constipation-predominant irritable bowel syndrome: the systematic investigation of gastrointestinal diseases in china (silc). |
| PubMedID- 23090647 | Linaclotide, a potent guanylate cyclase c agonist, is a therapeutic peptide approved in the united states for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. |
| PubMedID- 21902826 | Our patient also had a history of chronic constipation that was attributed to irritable bowel syndrome, and had been treated with laxatives and prokinetics without lasting success. |
| PubMedID- 23116208 | Background: treatment options that improve overall symptoms of irritable bowel syndrome with constipation (ibs-c) are lacking. |
| PubMedID- 25726441 | A total of 93 sf-36 questionnaires were analyzed, describing cases of irritable bowel syndrome with constipation (23%), functional constipation (27%), and unclassifiable constipation (51%). |
| PubMedID- 22759406 | We choose mosapride as a positive drug control based on: (1) it was reported to be superior to placebo for irritable bowel syndrome (ibs) patients with constipation, and it may have the potential to treat ibs patients with constipation and/or functional constipation [21]; and (2) a randomized controlled trial in china showed the same result [22], which indicates mosapride may be a better option than other medication for chinese population with functional constipation. |
| PubMedID- 26028974 | Optimal management of constipation associated with irritable bowel syndrome. |
| PubMedID- 21324760 | Results: stool form was significantly different in the irritable bowel syndrome patients with diarrhoea or constipation, and bowel movements were more frequent in the irritable bowel syndrome patients than in the healthy subjects. |
| PubMedID- 23641133 | Linaclotide (linzess) for irritable bowel syndrome with constipation and for chronic idiopathic constipation. |
| PubMedID- 24001336 | Linaclotide-a novel secretagogue in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. |
| PubMedID- 23464519 | irritable bowel syndrome with constipation (ibs-c) and chronic idiopathic constipation (cic) are highly prevalent gastrointestinal disorders associated with health, economical and social problems. |
| PubMedID- 20163375 | Background: renzapride, a 5-hydroxytryptamine type-4 (5-ht(4)) receptor agonist and 5-ht(3) receptor antagonist, has been proposed as a new treatment of irritable bowel syndrome with constipation (ibs-c). |
| PubMedID- 24943204 | Background: historically, measures of symptom severity of irritable bowel syndrome with constipation (ibs-c) in clinical trials have not met the evidence requirements described in the fda guidance on patient-reported outcomes (pros), which describes the evidentiary requirements and review criteria for patient-reported outcome measures intended to support product approval or labelling claims. |
| PubMedID- 25237424 | Background: irritable bowel syndrome with constipation (ibs-c), a chronic functional gastrointestinal disorder, has been shown to negatively affect work productivity and impair daily activity, resulting in a substantial burden for patients and employers. |
| PubMedID- 20863829 | Linaclotide is a first-in-class, orally administered 14-amino acid peptide that is in development for the treatment of irritable bowel syndrome with constipation and chronic constipation. |
| PubMedID- 25538778 | The effect of biofeedback therapy on dyssynergic constipation in patients with or without irritable bowel syndrome. |
| PubMedID- 24351035 | Effect of linaclotide in irritable bowel syndrome with constipation (ibs-c): a systematic review and meta-analysis. |
| PubMedID- 24840367 | irritable bowel syndrome with constipation and chronic functional constipation are common digestive disorders that negatively impact quality of life and account for billions of dollars in health care costs. |
| PubMedID- 24252578 | Patients suffering from irritable bowel syndrome with constipation reported higher depression scores (18.8 +/- 1.4 vs 12.7 +/- 1.3, p=0.002) and higher symptom intensity scores for constipation (6.2 +/- 0.3 vs 4.3 +/- 0.4, p<0.001), bloating (6.7 +/- 0.3 vs 3.3 +/- 0.4, p<0.001) and abdominal pain (6.0 +/- 0.3 vs 2.7 +/- 0.4, p<0.001) than patients with functional constipation. |
| PubMedID- 23816770 | Background: irritable bowel syndrome with constipation (ibs-c) and chronic idiopathic constipation (cic) are common functional bowel disorders. |
| PubMedID- 23198977 | Objectives: the aims were: firstly, to review the definition and diagnosis of irritable bowel syndrome with constipation (ibs-c, a subtype of ibs); secondly, to critically assess current therapies for ibs-c with a focus on effectiveness for abdominal pain; and thirdly, to review clinical studies evaluating the efficacy of linaclotide, a therapy recently approved by the us food and drug administration for the treatment of adults with ibs-c and chronic idiopathic constipation and the european medicines agency for the symptomatic treatment of moderate to severe ibs-c in adults, and in development for treatment of ibs-c worldwide. |
| PubMedID- 21765950 | Tegaserod is an agonist of the serotonin receptor 5-hydroxytryptamine 4 (5-ht4) and has been used for treating chronic constipation in patients with irritable bowel syndrome and chronic idiopathic constipation [31], [32]. |
| PubMedID- 24833940 | Linaclotide: a new option for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation in adults. |
| PubMedID- 26533542 | Diagnosis and management of moderate-to-severe irritable bowel syndrome with constipation (ibs-c) in germany: results from the ibis-c study. |
| PubMedID- 24623286 | The high number of constipation predominant irritable bowel syndrome and very low number of diarrhea predominant irritable bowel syndrome patients might be the reason for statistical non-significance since alpha2-adrenergic receptor gene is found to be responsible for mediating intestinal antisecretory action and probably is involved in the pathogenesis of diarrhea predominant irritable bowel syndrome. |
| PubMedID- 26016701 | irritable bowel syndrome with constipation (ibs-c) and chronic idiopathic constipation (cic) are two common functional gastrointestinal disorders that impair quality of life and pose a significant economic burden to the health care system. |
| PubMedID- PMC4350137 | We conclude that visceral hypersensitivity is likely to be a primary cause of constipation in rats with irritable bowel syndrome with constipation. |
| PubMedID- 24833931 | irritable bowel syndrome with constipation (ibs-c) affects approximately 5% of the population in western countries. |
| PubMedID- 23710967 | irritable bowel syndrome (ibs) with constipation was associated with pain in the left flank and patients were less likely to report pain in the right hypochondrium. |
| PubMedID- 21805417 | Postprandial platelet-poor plasma 5-hydroxytryptamine concentrations during diarrhea and constipation periods of alternatingtype irritable bowel syndrome patients. |
| PubMedID- 22251419 | Background: irritable bowel syndrome with constipation (ibs-c) significantly decreases quality of life and the ability to perform daily living activities. |
| PubMedID- 24684643 | Background: the prevalence of irritable bowel syndrome with constipation (ibs-c) is estimated to be between 4.3% and 5.2% among adults in the united states. |
| PubMedID- 23859757 | Hence, there remains an unmet need for well-tolerated and effective treatments for irritable bowel syndrome with constipation that target abdominal symptoms, including abdominal pain and bowel symptoms. |
| PubMedID- 24090017 | The european medicines agency has authorized its indication for the symptomatic treatment of moderate to severe irritable bowel syndrome with constipation in adults. |
| PubMedID- 20050846 | Tegaserod (teg), a 5-hydroxytryptamine type-4 (5-ht(4)) receptor partial agonist, represents a novel treatment for irritable bowel syndrome with constipation and chronic constipation. |
| PubMedID- 23835436 | Randomized clinical trial: macrogol/peg 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. |
| PubMedID- 24693271 | New treatment option for irritable bowel syndrome with constipation and chronic idiopathic constipation. |
| PubMedID- 23672677 | In the present issue of neurogastroenterology & motility, the performance of the fda responder endpoint for clinical trials in irritable bowel syndrome with constipation was evaluated using data from two large phase iii clinical trials of linaclotide. |
| PubMedID- 22403016 | In most cases patients suffer from mild to moderate constipation or symptoms of irritable bowel syndrome. |
| PubMedID- 26533504 | Economic burden and quality of life of moderate-to-severe irritable bowel syndrome with constipation (ibs-c) in germany: results from the ibis-c study. |
| PubMedID- 24007408 | Introduction: irritable bowel syndrome with constipation (ibs-c) is associated with abdominal pain and infrequent spontaneous bowel movements. |
| PubMedID- 21303430 | The aim of this work was to perform a dose-finding study for lubiprostone for the treatment of constipation with or without irritable bowel syndrome (ibs) in japan. |
| PubMedID- 26555695 | Peptide-based therapeutics have been successfully developed against other molecular targets, as exemplified by the approval of pasireotide (signifor) for the treatment of cushing’s disease [13] and the disulfide-rich linaclotide (linzess®) for the treatment of irritable bowel syndrome with constipation (ibs-c) and idiopathic and chronic constipation [14]. |
| PubMedID- 24660576 | Treatment of constipation-predominant irritable bowel syndrome by focusing on the liver in terms of traditional chinese medicine: a meta-analysis. |
| PubMedID- 26294923 | By the nature of altered bowel habits, ibs is classified into subtypes including ibs-c, irritable bowel syndrome with constipation; ibs-d, irritable bowel syndrome with diarrhoea; ibs-m, mixed irritable bowel syndrome (with both diarrhea and constipation >25% of bowel movements); and ibs-a, alternating irritable bowel syndrome (bowel habits often vary over time) [1]. |
| PubMedID- 21446888 | Introduction: linaclotide is a novel intestinal secretagogue that is in the advanced stages of development for the treatment of irritable bowel syndrome with constipation (ibs-c) and chronic constipation. |
| PubMedID- 24433216 | Background: irritable bowel syndrome with constipation (ibs-c) represents a significant burden to patients and healthcare systems due to its prevalence and lack of successful symptomatic resolution with established treatment options. |
| PubMedID- 26038704 | Linaclotide (forest laboratories, inc.; ironwood pharmaceuticals inc.) has been approved by the u.s. food and drug administration (fda) for the treatment of irritable bowel syndrome (ibs) patients with constipation (ibs-c) and adults with chronic idiopathic constipation (cic). |
Page: 1 2